PHRM Stock Overview
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
PharmaTher Holdings Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.35 |
52 Week High | CA$0.43 |
52 Week Low | CA$0.08 |
Beta | 3.02 |
1 Month Change | 79.49% |
3 Month Change | 22.81% |
1 Year Change | 169.23% |
3 Year Change | 45.83% |
5 Year Change | n/a |
Change since IPO | 79.49% |
Recent News & Updates
Shareholder Returns
PHRM | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 7.7% | 13.4% | 0.6% |
1Y | 169.2% | 39.9% | 10.3% |
Return vs Industry: PHRM exceeded the Canadian Pharmaceuticals industry which returned 39.8% over the past year.
Return vs Market: PHRM exceeded the Canadian Market which returned 10.3% over the past year.
Price Volatility
PHRM volatility | |
---|---|
PHRM Average Weekly Movement | 19.7% |
Pharmaceuticals Industry Average Movement | 13.8% |
Market Average Movement | 8.5% |
10% most volatile stocks in CA Market | 18.6% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: PHRM's share price has been volatile over the past 3 months.
Volatility Over Time: PHRM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2019 | n/a | Fabio Chianelli | https://www.pharmather.com |
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.
PharmaTher Holdings Ltd. Fundamentals Summary
PHRM fundamental statistics | |
---|---|
Market cap | CA$30.86m |
Earnings (TTM) | -CA$4.74m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.5x
P/E RatioIs PHRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PHRM income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$4.74m |
Earnings | -CA$4.74m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.054 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did PHRM perform over the long term?
See historical performance and comparison